- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Eli Lilly diabetes drug Mounjaro back to shelf after two month shortage
![Eli Lilly diabetes drug Mounjaro back to shelf after two month shortage Eli Lilly diabetes drug Mounjaro back to shelf after two month shortage](https://medicaldialogues.in/h-upload/2023/01/11/750x450_197381-eli-lilly-2.webp)
America: Eli Lilly & Co said on Tuesday all doses of its new diabetes drug Mounjaro were now available with wholesalers having inventory on hand after a two-month-long shortage.
"Because Mounjaro is still a launch product with dynamic demand, some pharmacies may continue to experience intermittent delays from time to time," Eli Lilly told Reuters in an emailed statement.
In December, the U.S. health regulator had added Mounjaro to its list of drugs facing shortages, highlighting Lilly's struggles to meet booming demand for the newly approved diabetes injection.
Due to its potential to help patient lose weight, Mounjaro is being recommended by doctors for that purpose even though it has not been explicitly approved as an obesity treatment in a common practice known as off-label prescribing, according to a report by Bloomberg News.
Read also: Eli Lilly gets CDSCO panel nod to study anticancer drug Imlunestrant
Lilly said it did not promote or encourage the off-label use of any of its medicines.
Mounjaro was approved in the United States last May to help people with type 2 diabetes control their blood sugar levels. The company anticipates the drug, which has the common name tirzepatide, to get nod for obesity, an even bigger market, next year.
Read also: CDSCO panel seeks data for Eli Lilly's anticancer drug selpercatinib
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751